Earnings Call Excerpt
Oxygen Biotherapeutics, Inc. (OXBO)
The Wall Street Analyst Forum Call Transcript
November 18, 2008, 11:10 am ET
Executives
Chris Stern – Chairman and CEO
Unidentified Speaker
For the benefit of all, I would like to go ahead and introduce the next company in this morning’s program; Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets, including traumatic brain injury, sickle cell crisis pain, wound care, trauma, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes. So, without any further introduction, I would like to introduce Chris Stern, Chairman of the company, and Charles Seeman, Chief Financial Officer.
Chris Stern
Thank you. Well, quite a stretch from electronics to biomedical. We are an 18-year old public company in the sectors of oxygen biotherapeutics. Core technology was developed up until 1991 by Lee Clark. And those of you who have seen the movie via disc may have seen that little rat here. That’s exactly the rat that was actually diving into perfluorocarbon and actually oxygenated by perfluorocarbon and surviving. And you see the fish on top. That’s what’s the fluorocarbon does, they carry oxygen. They are much heavier than water and their molecules are very, very small. Our molecules are four times smaller than a red blood cell. And thus it was logical to conclude that the company could actually develop a product being able to replace blood. So, the company initially was called Synthetic Blood. And we developed indications and it became apparent that synthetic blood probably would not be our primary indication, but carrying oxygen to wherever the body is depressed.
Now in an ischemic situation, where you lack oxygen the body sends a signal. So, if you have a stroke, a heart attack, or traumatic brain injury, body sends a signal to the system and the signal says, send the oxygen. Now in all these cases, one thing is clocked, that isn’t altered. So, there is no oxygen getting to that system. So, you need a bypass. It’s like a New York street. Try to get there is a limo, you can’t, but if you are on a bicycle you can. We have a bike and we are supercharged and superfast, 50 times faster than a red blood cell, and loads oxygen 50 times faster, wherever it’s needed. Now this opens up, of course a vast variety of indications. And that was a problem of the company, so many indications we didn’t focus. For 18 years, the company invested into research, basic research, specific research, some trials, and never made a buck. While research companies have an end point, and these are scientific end points, we want to prove this. We want to prove that – I am not a research guy, I am business guy and I have one signal end point, it is green and it has a number on it. As probably that’s what the investors want.
- To read the full transcript on Seeking Alpha, click here »
